Dabrafenib/Trametinib Combo Wins EU Approval for BRAF+ NSCLC

April 3, 2017 – The European Union (EU) approved the combination of dabrafenib and trametinib for patients with BRAF V600-positive advanced or metastatic non–small cell lung cancer (NSCLC). Novartis, maker of both drugs, reported in a statement that this is the first targeted treatment approved in all 28 EU member states for use in this specific patient population. “Today’s approval represents an important milestone for the lung cancer community, especially … (leggi tutto)